July 11, 2012 – Ongoing research involving a new mesothelioma treatment may provide asbestos victims hope in the fight against the deadly disease. As reported in the online medical journal Plos One, an experimental anti-cancer drug called Perifosine may offer a new way to treat malignant mesothelioma, either alone or in combination with other treatments.
Perifosine was tested on human mesothelial cells to determine the drug’s effectiveness in treating the devastating disease caused by asbestos exposure. The researchers found that when Perifosine was administered orally, it interfered with the growth of the mesothelioma cells. Perifosine’s effect was even more successful when the cancer cells were treated with Perifosine along with Cisplatin, a chemotherapy drug.
Perifosine is currently in a Phase 3 clinical trial and has been given Orphan Drug and Fast Track status. In the phase 3 clinical trial, the experimental study drug will be given to large groups of people to confirm its effectiveness, monitor side effects and compare it to other commonly used treatments. Researchers will collect information that will allow Perifosine to be used safely.
Shein Law – Lawyers Focused on Asbestos-Related Injuries in Pennsylvania and New Jersey
Every year approximately 2,500 Americans are diagnosed with mesothelioma. If you or one of your loved ones is diagnosed with mesothelioma, you need an experienced, knowledgeable and dedicated asbestos lawyer to help you fight for the financial compensation you deserve from those responsible for your injuries. The Philadelphia mesothelioma lawyers at Shein Law provide residents of Pennsylvania and New Jersey with zealous representation and have obtained significant settlements and verdicts for clients with asbestosis, lung cancer, mesothelioma and other asbestos-related illnesses. For a thorough review of your case, contact Shein Law today online or call toll free at 877-SHEINLAW (743-4652).